CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2046
Issued: 2026-10-12

PRODUCT IDENTIFICATION

PRODUCT
Retatrutide 30 mg

SKU / INTERNAL CODE
CRF-2026-2046

PRESENTATION
Lyophilised powder, 30 mg vial

BATCH NUMBER
LOT-2610-2046

CLIENT
veltispeptides.mx

SAMPLE RECEIVED
2026-10-07

ANALYSIS DATE
2026-10-10

PRODUCTION DATE
2026-10-05

ISSUED
2026-10-12

EXPIRY / RETEST
2028-10-12

MOLECULAR FORMULA
C221H342N46O68

MOLECULAR WEIGHT
4731.36

CAS NUMBER
2381089-83-2

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Waters ACQUITY · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C4 2.1×100mm | Temperature: 60°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.3 mL/min | Retention time: 14.2 min

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2046
Issued: 2026-10-12

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.6%	PASS
Quantity	95.0-105.0%	29.9 mg (99.7%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	4732.4 | Observed: 4732.6 | Δ +0.20 Da	PASS
Sequence Coverage (MS/MS)	≥95% | 98%	PASS
Key fragments	b12 1418.7 · b21 2431.2 · y14 1613.8 · y27 3142.6	PASS
Modifications	acylation sites intact; no truncation above 0.2%	PASS

RESEARCH USE ONLY - NOT FOR HUMAN OR VETERINARY USE

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb		<0.05 µg/g	PASS
As		<0.10 µg/g	PASS
Cd		<0.02 µg/g	PASS
Hg		<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.23 EU/mg | PPC recovery 88%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

High-dose presentation. Dysesthesia signal reported at 12 mg in Phase 3 - dosing reference only.

crafa

CRAFA